Dear friends of the Agency,

IARC’s vision of a world where fewer people develop cancer is fully aligned with the European Union (EU) approach to cancer prevention, treatment, and care. Ten EU-funded projects involving IARC started in 2022, and, at the time of writing, a further six EU-funded projects have been approved to start in 2023: DISCERN (Discovering the Causes of Three Poorly Understood Cancers in Europe), TOGAS (Towards Gastric Cancer Screening Implementation in the European Union), PRAISE (Prostate Cancer Awareness and Initiative for Screening Europe), EU cervScreen QA (European Cervical Screening Quality Assurance Update), 4P-CAN (Personalized Cancer Primary Prevention Research through Citizen Participation and Digitally Enabled Social Innovation), and CCI4EU (Comprehensive Cancer Infrastructures for the European Union).

At an international level, I am delighted to share with you the outcomes of meetings I attended in 2022. Talks with United States National Cancer Institute units and external partners in Washington, DC, identified several areas in which to strengthen our cooperation, including training and capacity-building, the IARC COVID-19 and Cancer Initiative, implementation science, and the Cancer Moonshot Initiative. The 5th Combined Gulf Cancer Conference in Sharjah, United Arab Emirates, provided a welcome opportunity to meet with high-level partners to discuss strengthened cooperation on cancer research and the potential IARC membership of nations in the Gulf region.

Finally, the past year has seen the IARC community prepare for our move to the Nouveau Centre building. It has been an immense challenge, which today we can truly call a great success! I look forward to welcoming you all to our new headquarters in 2023. Sending you my best wishes for the New Year.

Best regards,

Dr Elisabete Weiderpass
IARC Director
<table>
<thead>
<tr>
<th>IARC News</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>An overview of IARC’s research highlights and achievements in 2022</strong></td>
</tr>
<tr>
<td>Read more</td>
</tr>
<tr>
<td><strong>IARC GICR launches new Collaborating Centres in Côte d’Ivoire, Kenya, and South Africa to improve access to cancer data</strong></td>
</tr>
<tr>
<td>Read more</td>
</tr>
<tr>
<td><strong>IARC reports marked differences in survival among patients diagnosed with cancer in countries in transition worldwide</strong></td>
</tr>
<tr>
<td>Read more</td>
</tr>
<tr>
<td><strong>IARC marks Cervical Cancer Awareness Month 2023</strong></td>
</tr>
<tr>
<td>Read more</td>
</tr>
<tr>
<td><strong>Global and regional estimates of maternal orphans attributed to cancer mortality in 2020: 1 million new maternal orphans due to cancer in 2020</strong></td>
</tr>
<tr>
<td>Read more</td>
</tr>
<tr>
<td><strong>The global cervical cancer burden in 2020 and recent trends in incidence: a baseline assessment for monitoring the WHO Global Cervical Cancer Elimination Initiative</strong></td>
</tr>
<tr>
<td>Read more</td>
</tr>
</tbody>
</table>
IARC supports Europe’s Beating Cancer Plan

Supporting cancer screening programmes and prevention measures
IARC is coordinating the CanScreen-ECIS project to improve access to cancer screening programmes in the EU and collect harmonized cancer screening performance data, and is also coordinating the development of the 5th edition of the European Code Against Cancer, which will add population-level prevention measures to its cancer prevention advice. Also in support of the Code, IARC is participating in the BUMPER project to support the development of the flagship EU Mobile App for Cancer Prevention.

Mobilizing knowledge for EU-funded projects
In 2023, IARC is bringing its expertise in knowledge mobilization to the WCT EVI MAP project (Mapping the Evidence for the WHO Classification of Tumours: a Living Evidence Gap Map by Tumour Type) and to the EUROHELICAN project (Accelerating Gastric Cancer Reduction in Europe through Helicobacter pylori Eradication), which will result in an IARC Working Group Report on implementation of H. pylori test-and-treat strategies. In the SEAWave (Scientific-Based Exposure and Risk Assessment of Radiofrequency and Millimetre-Wave Systems from Children to Elderly (5G and Beyond)) project, IARC will coordinate a risk assessment on exposures to 5G electromagnetic fields.

Developing European research infrastructure
Through the canSERV project, IARC is developing an operational framework for an access platform for cancer research services. IARC is already contributing to new exposome research tools as a consortium partner in the EXPANSE and Human Exposome Assessment Platform projects. Finally, IARC is also shaping the future research landscape through its role with the UNCAN.eu project to build a European research agenda for cancer prevention and treatment.
Novel biomarkers for colorectal cancer

IARC is participating in the ColoMARK project to improve the development of biomarkers of colorectal cancer, and will provide training in statistics and machine learning for the young researchers in the ColoMARK network.

Read more

Cancer screening in eastern Europe

IARC is providing expertise in health infrastructure and cancer screening programmes to the ministries of health of Latvia and Slovakia in the Improving Cancer Care Coordination and Screening in Latvia and Slovakia (ICCCS) project.

Read more

Meet FAIR Frog and Data Gator!

Developed by IARC for the Human Exposome Assessment Platform project, “Swamped!” is a video series on applying FAIR data principles to scientific research, with helpful data management advice.

Watch videos

The IARC Cross-Cutting Working Group on Cancer Prevention Knowledge Translation and Transfer produces the Evidence Summary Briefs series to call attention to scientific studies leading to cancer prevention.

Click here to subscribe and receive future IARC Evidence Summary Briefs

#cancerresearchthatmatters

Was this email forwarded to you?
Subscribe to our newsletter to stay informed

Sign up now

Copyright © 2023 International Agency for Research on Cancer, All rights reserved.

You are receiving this email because you have engaged with IARC in the past or because you opted in on our website.

Our mailing address is:
25 avenue Tony Garnier
Want to change how you receive these emails? You can update your preferences or unsubscribe from this list.

Kindly note that the WHO/IARC privacy policy applies.